Modern antiretroviral therapy (ART) has transformed HIV from a fatal diagnosis into a manageable chronic condition — with consistent treatment, life expectancy approaches normal and viral suppression makes sexual transmission essentially zero (U=U: undetectable equals untransmittable). The MedsBase HIV Medication catalogue carries the major NRTI backbones, integrase inhibitors, complete-regimen tablets, and selected adjuncts used in modern HIV treatment and PrEP. All products are supplied by WHO-GMP sertifioiduilta valmistajilta.
NRTI backbone — the foundation of ART and PrEP. Tenofovir disoproxil fumarate + emtricitabine (TDF/FTC) is the most-used NRTI backbone globally — used both as part of HIV treatment regimens and as daily pre-exposure prophylaxis (PrEP). We stock Tenof EM ja Ricovir EM. Tenofovir alafenamide + emtricitabine (TAF/FTC) — the newer prodrug with better renal and bone safety profile — is available as Tavin EM ja Tenvir AF. Lamivudine monotherapy (3TC, the building-block NRTI for HBV co-treatment and selected paediatric protocols) as Lamivir. Selaa PrEP-lääkkeet category for the full PrEP-formatted range and our hub guide Parhaat PrEP-lääkkeet 2026.
Integrase strand-transfer inhibitors (INSTI). Modern first-line ART pairs an NRTI backbone with an integrase inhibitor (dolutegravir, bictegravir, or raltegravir) — high barrier to resistance, fewer drug interactions, and excellent tolerability. Raltegravir 400 mg is stocked as Ralmac 400 ja Instgra.
Complete single-tablet regimens (STRs). Single-tablet once-daily regimens simplify ART and improve adherence. Avonza combines tenofovir + lamivudine + efavirenz (TLE — the WHO first-line regimen for many years and still widely used in resource-limited settings). Teravir provides tenofovir + lamivudine. Taficita delivers TAF + emtricitabine + bictegravir-class integrase inhibitor, the modern preferred first-line regimen.
Other NRTIs and adjuncts. Lamivudine + zidovudine combination (AZT/3TC) is stocked as Hivus-LR. Ritonavir-boosted protease inhibitor combinations as Ritocom. Selected legacy regimens including Trioday remain catalogued for switch / continuation use.
How to choose — and important caveats. Modern WHO and DHHS first-line guidance is dolutegravir or bictegravir + TAF/FTC (or TDF/FTC where TAF unavailable). Switch from older regimens (efavirenz-based, AZT-based) is appropriate for most patients but should be done in coordinated HIV-care setting. PrEP requires baseline HIV testing (negative status) and quarterly re-testing — this is essential to avoid integrase-resistance emergence in undiagnosed acute HIV. STI co-screening, hepatitis B status, renal function, and bone-density assessment are part of standard HIV / PrEP care.
Critical. Do not source HIV medication without ongoing engagement with an HIV-care provider — adherence monitoring, viral load surveillance, CD4 monitoring, drug-interaction review, and resistance testing are essential for long-term safety and effectiveness. Hepatitis B co-infection requires careful regimen choice (TDF/FTC and TAF/FTC also treat HBV; abrupt discontinuation can cause severe HBV flare). Pregnancy: most modern regimens are safe; integrase inhibitors are increasingly preferred.
All MedsBase HIV Medication products ship from WHO-GMP sertifioiduilta valmistajilta diskreetisti pakattuna ja ne kuuluvat Reshipment Assurance Policy -politiikkamme piiriin.
2026 ostajan opas: Katso lyhytlistamme Best HIV Treatment Regimens 2026 luokitelluille valinnoille, vertailutaulukolle, annostusohjeille ja päätöksenteon apuvälineelle.